BCL-2 (B-cell lymphoma 2) Inhibitors Market Share

North American Market Forecast

BCL-2 (B-cell lymphoma 2) inhibitors market in North America is predicted to account for the largest share of 56% by 2036 impelled by the increasing product approvals. For instance, in 2020, The Food and Drug Administration approved venetoclax (VENCLEXTA, AbbVie Inc., and Genentech Inc.) after it was granted accelerated approval for use in 2018. Furthermore, the recommended dose of venetoclax is determined by the combination regimen that can be used in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly diagnosed acute myeloid leukemia (AML) in people 75 years of age or older.

European Market Statistics

The Europe BCL-2 inhibitors market is estimated to be the second largest, during the forecast timeframe led by increasing health awareness. Moreover, Europe has developed several innovative and effective solutions to promote good health and well-being, and to create awareness about the importance of healthy lifestyles. This, as a result, may drive demand for BCL-2 inhibitors for several diseases prevailing in the region.

Frequently Asked Questions (FAQ)

Rising cases of Diffuse B-cell Lymphoma and the growing government initiatives are the major factors driving the growth of the market.

The market size of BCL-2 (B-cell lymphoma 2) Inhibitors is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2024-2036.

The major players in the market are Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, Seagen Inc., Servier, AbbVie Inc., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG.

The combination therapy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

BCL-2 (B-cell lymphoma 2) Inhibitors Market Share